GlassScriptPhysician profile
Sarah Alexander
NPI 1801022124
$4,708.43
in general payments reported to CMS, 2019-2025
27 companies · $1,351 in 2025
The $1,351 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $209 · 2021: $1,057 · 2022: $586 · 2023: $315 · 2024: $715 · 2025: $1,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,381.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,602.51 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $512.44 | 2019-2023 | Xarelto |
| Aop Health US, LLC | $391.35 | 2025 | Rapiblyk |
| Amgen INC. | $381.37 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $310.66 | 2019-2022 | |
| Pfizer INC. | $259.82 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $164.62 | 2020-2025 | Wainua, Farxiga |
| Novo Nordisk INC | $157.73 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.39 | 2020-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $89.82 | 2021-2022 | |
| Bridgebio Pharma, INC. | $86.50 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $79.58 | 2019-2024 | |
| Vifor Pharma, INC. | $70.24 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $63.47 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $55.16 | 2020-2024 | Camzyos |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $52.56 | 2022-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $52.36 | 2024 | Arcalyst |
| Abbott Laboratories | $40.99 | 2021-2023 | Cardiomems |
| Esperion Therapeutics, INC. | $40.57 | 2021-2025 | Nexletol |
| Boston Scientific Corporation | $39.88 | 2021-2025 | Watchman Flx |
| Scpharmaceuticals INC. | $24.21 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $22.63 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.38 | 2025 | |
| Angiodynamics, INC. | $19.00 | 2021 | |
| Lilly USA, LLC | $17.43 | 2025 | Mounjaro |
| Amryt Pharma Holdings LTD | $15.37 | 2021 | |
| Medtronic Vascular, INC. | $13.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.